

Journal of Pharmaceutical Sciences



MARCH 1977

VOLUME 66 NUMBER 3

MARY H. FERGUSON
Editor

L. LUAN CORRIGAN
Assistant Editor

SHELLY ELLIOTT
Production Editor

JANET D. SHOFF
Copy Editor

EDWARD G. FELDMANN
Contributing Editor

SAMUEL W. GOLDSTEIN
Contributing Editor

LELAND J. ARNEY
Director of Publications

EDITORIAL ADVISORY BOARD

JOHN AUTIAN HARRY B. KOSTENBAUDER

NORMAN R. HERBERT A. LIEBERMAN
FARNSWORTH

WILLIAM O. FOYE DAVID E. MANN, JR.

WILLIAM J. JUSKO GERALD J. PAPARIELLO

The *Journal of Pharmaceutical Sciences* is published monthly by the American Pharmaceutical Association at 2215 Constitution Ave., N.W., Washington, DC 20037. Second-class postage paid at Washington, D.C., and at additional mailing office.

All expressions of opinion and statements of supposed fact appearing in articles or editorials carried in this journal are published on the authority of the writer over whose name they appear and are not to be regarded as necessarily expressing the policies or views of the American Pharmaceutical Association.

Offices—Editorial, Advertising, and Subscription Offices: 2215 Constitution Ave., N.W., Washington, DC 20037. Printing Offices: 20th & Northampton Streets, Easton, PA 18042.

Annual Subscriptions—United States and foreign, industrial and government institutions \$50, educational institutions \$50, individuals *for personal use only* \$30; single copies \$5. All foreign subscriptions add \$5 for postage. Subscription rates are subject to change without notice. Members of the American Pharmaceutical Association may elect to receive the *Journal of Pharmaceutical Sciences* as a part of their annual \$60 (foreign \$65) APHA membership dues.

Claims—Missing numbers will not be supplied if dues or subscriptions are in arrears for more than 60 days or if claims are received more than 60 days after the date of the issue, or if loss was due to failure to give notice of change of address. The Association cannot accept responsibility for foreign delivery when its records indicate shipment has been made.

Change of Address—Members and subscribers should notify at once both the Post Office and the American Pharmaceutical Association, 2215 Constitution Ave., N.W., Washington, DC 20037, of any change of address.

© Copyright 1977, American Pharmaceutical Association, 2215 Constitution Ave., N.W., Washington, DC 20037; all rights reserved.

HOW MUCH IS "ENOUGH"?

For the past year or two, articles, speeches, testimony, and assorted other means of communication have been rife with comment and opinion to the effect that either additional regulation is needed in the area of drug discovery and introduction or, conversely, that already drug discovery and introduction are subjected to excessive regulation.

On the one side, those who advocate additional legal controls present persuasive arguments based upon statistics showing significant toxicity, adverse reactions, and related harmful effects associated with a particular drug which often come to light only after its widespread or long-term use. On the other hand, opponents to further regulation present equally persuasive arguments that already drug innovation has been inhibited, a so-called "drug lag" has developed, and patients are presently being denied the benefit of important new drug discoveries, all due to what they regard as the excessively restrictive current regulations which delay or prevent new drug marketing approval.

It is, of course, just such differences of viewpoint which are said "to make a horse race." All of this reminds us of an anecdote which may or may not have basis in fact but certainly is pertinent. We were told that the river which ran through a small rural town was closed to swimming by the local health department on grounds that it was polluted and a menace to health. The town leaders went to extensive effort to correct the problem and to clean up their river. But when they then requested the health department to open the river to swimming, their request was again denied—this time with the explanation that the river constituted the source of the local drinking water supply and it would be unsanitary, therefore, to permit swimming!

Whether or not such an incident actually occurred, we do know for a fact that rather comparable incidents repeatedly have happened in the area of drug standards. For example, on many occasions, critics from the drug industry have alleged that official compendia specifications were insufficient to assure an aspect of drug quality whether it be potency, identity, bioavailability, stability, or some other related characteristic. Subsequently, the compendia proposed adoption of either a new or more stringent specification in order to remedy the alleged deficiency. Not uncommonly, such proposals then met with objection from the very same critics on grounds that such test requirements were excessive, or would contribute prohibitively to manufacturing costs, or even that the proposed requirements were too "severe" because their own products could not meet the new standard!

It is well to recognize that the genesis of any proposed new law or regulation generally can be traced back to some sort of abuse or problem. For example, the Good Laboratory Practice regulations which were discussed in our February editorial were the direct result of falsified test data submitted to FDA in support of certain New Drug Applications. Consequently, as a general observation, most disinterested parties would tend to feel that society and government must impose regulatory controls to avoid problems or to prevent repeated abuses.

Our view tends to concur but, at the same time, we also recognize that such regulations must be reasonable and properly tempered to avoid excessive restrictions which will unduly inhibit and discourage future research by destroying legitimate incentives. Drug regulation is particularly susceptible to "overkill," and care must be exercised to avoid a result which might be even more disastrous than the problem it is intended to control.